Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812175 · ClinicalTrials.gov registry record
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 3,371
- Enrollment target
NCT00812175 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 3,371 participants.
The verdict
NCT00812175 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 3,371 participants
- Enrollment target
Study Summary
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,371 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812175
The ClinicalTrials.gov registry entry for NCT00812175 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00812175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812175 about?
NCT00812175 is a clinical study titled "Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib". In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
What is the current status of trial NCT00812175?
This trial is currently completed. The enrollment target is 3,371 participants. The study started on 2009-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00812175?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00812175?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.